An integrin β3-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition

Seguin, Laetitia, Kato, Shumei, Franovic, Aleksandra, Camargo, M. Fernanda, Lesperance, Jacqueline, Elliott, Kathryn C., Yebra, Mayra, Mielgo, Ainhoa +12 more·2014·Nature Cell Biology
DOI 10.1038/ncb2953

Cited by (374)

Items 301–374 of 374

  1. Towards an Integrated Understanding of Epidermal Growth Factor Receptor Biology for Radiation Therapy: Integrins Enter
    Henning Willers, Theodore Sunki Hong · 2015 · JNCI Journal of the National Cancer Institute
  2. Is Immunohistochemical Galectin-3 Expression Associated with the Epithelial–Mesenchymal Transition in High- and Low-Grade Invasive Urothelial Carcinomas of the Bladder?
    Merve Cin, Ayşenur Akyıldız İğdem, Sibel Bektaş, Özgecan Gündoğar, Selçuk Cin, Neslihan Komut, Buğra Çetin · 2024 · Diagnostics
  3. Aidi injection inhibits the migration and invasion of gefitinib-resistant lung adenocarcinoma cells by regulating the PLAT/FAK/AKT pathway
    Jingyuan Zhang, Siyun Yang, Xiaodong Chen, Fanqin Zhang, Siyu Guo, Chao Wu, Tieshan Wang, Haojia Wang, Shan Lu, Chuanqi Qiao et al. · 2025 · Chinese Medicine
  4. Profound connection between atherosclerosis and cancer: The role of galectin-3: A review
    Xiaoyu Wang, Benkai Xin, Jingtong Yang, Xin Hu, Youzhong Wan · 2025 · International Journal of Biological Macromolecules
  5. Integrins in cancer: insights into mechanisms and therapeutic potential
    Parth Agarwal, Rachana Raman, Prasoon Agarwal, Vijendra Prabhu, Praveen Kumar · 2026 · Cell Communication and Signaling
  6. Overcoming Nutrient Stress: Integrin αvβ3-Driven Metabolic Adaptation Supports Tumor Initiation
    Elena Rainero · 2024 · Cancer Research
  7. Targeting Integrin-Dependent Adhesion and Signaling with 3-Arylquinoline and 3-Aryl-2-Quinolone Derivatives: A new Class of Integrin Antagonists
    Sandrine Fiorucci, Xiaochen Lin, Karin Sadoul, Guy Fournet, Daniel Bouvard, Olga Vinogradova, Benoı̂t Joseph, Marc R. Block · 2015 · PLoS ONE
  8. Contribution of nuclear events in generation and maintenance of cancer stem cells: revisiting chemo-resistance
    Argha Manna, Shruti Banerjee, Poulami Khan, Apoorva Bhattacharya, Tanya Das · 2017 · The Nucleus
  9. Targeting the Achilles’ heel of drug-resistant cancer stem cells
    Laetitia Seguin, Maricel C. Gozo, Sara M. Weis, David A. Cheresh · 2014 · Cell Cycle
  10. Resistance to radiation enhances metastasis by altering RNA metabolism
    Ayush Kumar, Kensei Kishimoto, Hira Lal Goel, Christi A. Wisniewski, Rui Li, Brendan A Pacheco, Lihua Julie Zhu, William A. Flavahan, Arthur M. Mercurio · 2025 · Science Advances
  11. Selective targeting of NRF2-high pancreatic ductal adenocarcinoma with an NQO1-activatable prodrug
    Laura Antonucci, Kosuke Watari, Yechen Feng, Jingjing Qi, Mandy Zhu, Tingya Wang, Isabella Ng, Emily Vucic, Irene Riahi, Li Huang et al. · 2026 · Proceedings of the National Academy of Sciences
  12. The extracellular matrix in breast cancer
    Manzoor Ahmad Mir, Aabida Gul · 2022 · Elsevier eBooks
  13. Prediction of synergistic gemcitabine-based combination treatment through a novel tumor stemness biomarker NANOG in pancreatic cancer
    Jiongjia Cheng, Ting Zhu, Shaoxian Liu, Jiayu Zhou, Xiaofeng Wang, Guang‐Xiang Liu · 2024 · RSC Medicinal Chemistry
  14. Cell membrane sialome machinery and regulation of receptor tyrosine kinases in gliomas: The functional relevance and therapeutic perspectives
    Patrycja Jastrząb, Halina Car, Przemysław Wielgat · 2025 · Biomedicine & Pharmacotherapy
  15. A phase i study of ixazomib and erlotinib in patients with advanced solid tumors
    Shumei Kato, Jacob J. Adashek, Vivek Subbiah, Siqing Fu, Mianen Sun, Ly M. Nguyen, Elsa J. Brown, Timothy Anthony Yap, Daniel D. Karp, Sarina Anne Piha-Paul et al. · 2021 · Investigational New Drugs
  16. LC-MS/MS CHARACTERIZATION OF FORCED DEGRADATION PRODUCTS OF TUCATINIB, A NOVEL TYROSINE KINASE INHIBITOR: DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD
    Shaik Reehana, Korukonda Keerthi Sujana · 2022 · International Journal of Applied Pharmaceutics
  17. KRAS Addiction Promotes Cancer Cell Adaptation in Harsh Microenvironment Through Macropinocytosis
    Laetitia Seguin · 2022 · Sub-cellular biochemistry/Subcellular biochemistry
  18. Pancreatic cancer drug-sensitivity predicted by synergy of p53-Activator Wnt Inhibitor-2 (PAWI-2) and protein biomarker expression
    Jiongjia Cheng, John Richard Cashman · 2020 · Investigational New Drugs
  19. Advances in pancreatic cancer stem cells, tumor-associated macrophages, and their interplay
    2014 · Cancer Cell & Microenvironment
  20. Metastasis is a highly stressful process
    Alejandro D. Campos, Sara M. Weis, David A. Cheresh · 2020 · Cancer and Metastasis Reviews
  21. Editorial: A stake in the game: ADAM23 contributes to dendritic cell effectiveness in stimulating CD4+ T cell proliferative responses
    Joana Cabral, Matthew Dallas Griffin · 2016 · Journal of Leukocyte Biology
  22. The current understanding of KRAS oligomerization on membranes
    Nastazia Lesgidou, Michail Papadourakis, Nishita Mandal, Sepehr Dehghani‐Ghahnaviyeh, Camilo Velez‐Vega, José S. Duca, Zoe Cournia · 2025 · Current Opinion in Structural Biology
  23. Glycobiology-driven therapeutic targeting of glycan-binding proteins: mechanisms, diseases, and clinical translation
    Alyanna M. Popatia, Ahmad Sharanek, Arezu Jahani‐Asl · 2026 · Signal Transduction and Targeted Therapy
  24. First-Generation Tumor Xenografts: A Link Between Patient-Derived Xenograft Models and Clinical Disease
    Xin Dong, Peter W. Gout, Lu Yi, Yinhuai Wang, Yong Xu, Kuo Yang · 2017 · Molecular and translational medicine
  25. Unique hypoxia-tolerant subpopulations of adipose-derived stem cells: ITGB3+ cells
    Jiankun Cao, Yuming Shen, Zhigang Yang, Bo Pan, Zhenzhong Liu · 2022 · Journal of Plastic Reconstructive & Aesthetic Surgery
  26. The Many Roles of Ral GTPases in Ras-Driven Cancer
    David F. Kashatus · 2016 · Elsevier eBooks
  27. Inside a Metastatic Fracture: Molecular Bases and New Potential Therapeutic Targets
    Alessandro Bruschi, Andrea Sambri, Michele Fiore, Elisa Bubbico, Cristina Scollo, Andrea Pace, Renato Zunarelli, Andrea Montanari, Alberta Cappelli, Lorenzo Di Prinzio et al. · 2025 · Cancer Medicine
  28. Preadipocyte-induced upregulation of IGFBP5 enhances ovarian cancer tumorigenesis via CREB signaling
    Jennifer A. Waters, Cassidy Lucht, Sofia Howe, Gregory J. Jordan, Ixchel Urbano, Samuel F. Gilbert, Richard M. Cripps, Mikella Robinson, Carrie Danielle House · 2025 · iScience
  29. Integrin αvβ3-dependent pathogenic effect and therapeutic effects of DL-N2 combined with EGFR inhibitors in pancreatic adenocarcinoma
    Zilin Li, Sachin Kumar, San‐Nan Yang, Tung‐Cheng Chang, Linyi Huang, Ching‐Chung Ko, Yung‐Ning Yang, Chih-jung Yao, Dana R. Crawford, Fabio Gionfra et al. · 2026 · Journal of Translational Medicine
  30. Effects of Tumor Microenvironment on Lung Cancer Stem Cells: Bidirectional Regulatory Mechanisms
    Hongyi Lai, Ruihang Luo, Wei Zou, Xuyang Liu, Maosen Liu, Mingshan Liu, Jingtao Zhang · 2026 · Cancer Medicine
  31. RelB drives integrin-mediated stress tolerance and relapse in high-grade serous ovarian cancer
    Omar Lujano-Olazaba, Mikella Robinson, Gregory J. Jordan, Sofia Howe, Anna Platen, Cassidy Lucht, Dishant Vandra, Cecilia Gallo, Mena Shammas, Katelyn Shelby et al. · 2026 · Cell Reports
  32. Differential Splicing of Skipped Exons Predicts Drug Response in Cancer Cell Lines
    Edward R. Simpson, Steven Chen, Jill L. Reiter, Yunlong Liu · 2021 · Genomics Proteomics & Bioinformatics
  33. Relationship of the integrin profile of the primary tumor to metastasis to regional lymph nodes in breast cancer
    Marina V. Zavyalova, Gleb A. Kuznecov, Evgeniya S. Grigoryeva, Л. А. Таширева, Письменный Дмитрий Сергеевич, Перельмутер Владимир Михайлович · 2023 · Journal of Modern Oncology
  34. Effect of PAWI-2 on pancreatic cancer stem cell tumors
    John Richard Cashman, Emily A. Cashman · 2024 · Investigational New Drugs
  35. Integrin β5-positive cancer-associated fibroblasts promoting lung adenocarcinoma invasion leading to poor prognosis
    Saori Shibata, Chihiro Inoue, Yasuhiro Miki, Hirotsugu Notsuda, Hiromichi Niikawa, Yoshinori Okada, Takashi A. SUZUKI · 2025 · Pathology - Research and Practice
  36. A Cancer Stem Cell Perspective on Minimal Residual Disease in Solid Malignancies
    Maartje van der Heijden, Louis Vermeulen · 2019 · Resistance to targeted anti-cancer therapeutics
  37. Targeting the Ras-Ral effector pathway for cancer treatment
    Leanna R. Gentry · 2019 · Carolina Digital Repository (University of North Carolina at Chapel Hill)
  38. A Biomaterial Screening Approach Reveals Microenvironmental Mechanisms of Drug Resistance
    Alyssa D. Schwartz, Lauren E. Barney, Lauren Jansen, Thuy V. Nguyen, Christopher L. Hall, Aaron S. Meyer, Shelly R. Peyton · 2017 · bioRxiv (Cold Spring Harbor Laboratory)
  39. Predicting phenotype to mechanotype relationships in cells based on intracellular signaling network
    Esra Tiftik Karabay, Amy Turnlund, Jessica Grear, Stephanie I. Fraley, Parag Katira · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
  40. Integrin αV control of Cu homeostasis and cisplatin sensitivity
    Xinjian Lin, Xiying Shang, Stephen B. Howell · 2014 · Cell Cycle
  41. Function of latent transforming growth factor-β binding protein-2 (LTBP-2) in elastinogenesis and modulation of growth factor storage, expression and activity in normal and fibrotic tissues
    Mohamed Arshad Mohamed Sideek · 2016 · Adelaide Research & Scholarship (AR&S) (University of Adelaide)
  42. Novel technologies and their applications in biotechnology
    Yusuf Deeni, Tommaso Beccari, Munis Dündar, Jill S. Gartland, Michele Maffia, MariaPia Viola-Magni, Kevan M.A. Gartland · 2014 · ResearchOnline
  43. Personalized medicine: exploiting druggable vulnerabilities for KRAS-driven lung cancer
    Laetitia Seguin, Chloé C. Féral · 2018 · Oncoscience
  44. [Research Progress of New Generation EGFR-TKIs after Third-generation].
    Yuanyuan Liu, Yihui LI, Jiangong Wang · 2020 · PubMed Central
  45. Tumor-secreted versican co-opts myeloid IKKβ during metastasis
    Μάγδα Σπέλλα, Anne‐Sophie Lamort, Malamati Vreka, Antonia Marazioti, Ioannis Lilis, Giannoula Ntaliarda, Georgios Skiadas, Eleni Bouloukou, Georgia A. Giotopoulou, Mario A. A. Pepe et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  46. Association Between RAS-Like Proto-Oncogene B (RALB) Gene Expression and Methylation Levels in Saudi Autistic Children
    Aisha Alrofaidi, Raghad Alghamdi, Mona Ghonaim Alharbi, Khloud Mubarak Algothmi, Reem M. Farsi, Najla Ali Alburae, Magdah Ganash, Alawiah Mohammad Alhebshi, Fatemah Salem Basingab, Sheren A. Azhari et al. · 2021 · International Journal of Pharmaceutical and Phytopharmacological Research
  47. Immune-evasion of KRAS -mutant lung adenocarcinoma mediated by cAMP response element-binding protein
    Georgia A. Giotopoulou, Giannoula Ntaliarda, Antonia Marazioti, Ioannis Lilis, Foteini Kalogianni, Evanthia Tourkochristou, Nikolitsa Spiropoulou, Ioanna Giopanou, Μάγδα Σπέλλα, Marianthi P. Iliopoulou et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  48. Epithelial-mesenchymal transition and resistance to EGFR inhibitors
    Sheeba Jacob, Richard Kurupi, Anthony C. Faber · 2023 · Elsevier eBooks
  49. Data from FGFR Inhibition Overcomes Resistance to EGFR-targeted Therapy in Epithelial-like Cutaneous Carcinoma
    Adrià Bernat‐Peguera, Juan Navarro-Ventura, Laura Lorenzo-Sanz, Victoria da Silva-Diz, Mattia Bosio, Luís Palomero, Rosa Maria Penin, Diana Pérez Sidelnikova, Josep Oriol Bermejo, Miren Taberna et al. · 2023
  50. Data from FGFR Inhibition Overcomes Resistance to EGFR-targeted Therapy in Epithelial-like Cutaneous Carcinoma
    Adrià Bernat‐Peguera, Juan Navarro-Ventura, Laura Lorenzo-Sanz, Victoria da Silva-Diz, Mattia Bosio, Luís Palomero, Rosa Maria Penin, Diana Pérez Sidelnikova, Josep Oriol Bermejo, Miren Taberna et al. · 2023
  51. Data from Targeted Therapy to β3 Integrin Reduces Chemoresistance in Breast Cancer Bone Metastases
    Gregory C. Fox, Xinming Su, Jennifer L. Davis, Yalin Xu, Kristin A. Kwakwa, Michael H. Ross, Francesca Fontana, Jingyu Xiang, Alison K. Esser, Elizabeth Cordell et al. · 2023
  52. Protein‐Targeted Glycan Editing on Living Cells Disrupts KRAS Signaling
    Yiran Li, Fan Huo, Liusheng Chen, Haiqi Wang, Jianzhuang Wu, Peiwen Zhang, Nan Feng, Wei Li, Lan Wang, Yichun Wang et al. · 2023 · Angewandte Chemie
  53. Review on the molecular mechanism of talin- and integrin-dependent cancer invasion
    Zbigniew Baster, Lindsay Russell, Zenon Rajfur · 2023
  54. More than just a KRAS inhibitor: DCAI abrogates the self-renewal of pancreatic cancer stem cells in vitro
    Yuan Han Teh, Rui Jing, Rajesh Ramasamy, Kok Lian Ho, Sreenivasa Rao Sagineedu, Johnson Stanslas · 2023 · ONCOLOGIE
  55. Association of integrin expression in tumor tissue with hematogenic metastasis of breast cancer
    Marina V. Zavyalova, G. A. Kuznetsov, Evgeniya S. Grigoryeva, Л. А. Таширева, Письменный Дмитрий Сергеевич, Перельмутер Владимир Михайлович · 2024 · Siberian Journal of Oncology
  56. Integrin profle of circulating tumour cells in breast cancer patients
    Evgeniya S. Grigoryeva, Л. А. Таширева, V. V. Alifanov, Marina V. Zavyalova, Перельмутер Владимир Михайлович · 2024 · Siberian Journal of Oncology
  57. RALGEF inhibitors suppress RAS-driven pancreatic cancer and metastasis
    Howard Donninger, Rachel Ferrill, Becca V. Baby, Katie R Hobbing, William L. Dean, Nagaraju Miriyala, Raphael Jigo, Joseph A. Burlison, John O. Trent, Rob Monsen et al. · 2025 · Journal of Biological Chemistry
  58. TANK-binding kinase 1 inhibitor GSK8612 suppresses platelet function and thrombosis via the ERK/P38 signaling pathway
    Chengying Gu, Liang Wang, Ran Tian, Hao Qian, Ming Wu, Xueqing Zhu, Sainan Li, Wei Zuo, Zhenyu Liu, Shuyang Zhang · 2025 · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
  59. Additional file 3 of Identification of CEACAM5 as a stemness-related inhibitory immune checkpoint in pancreatic cancer
    Hao Shi, Tsang, Yiusing, Yang, Yisi · 2023 · Figshare
  60. Additional file 5 of Identification of CEACAM5 as a stemness-related inhibitory immune checkpoint in pancreatic cancer
    Hao Shi, Tsang, Yiusing, Yang, Yisi · 2023 · Figshare
  61. Additional file 1 of Identification of CEACAM5 as a stemness-related inhibitory immune checkpoint in pancreatic cancer
    Shi, Haojun, Tsang, Yiusing, Yang, Yisi · 2023 · Figshare
  62. Additional file 4 of Identification of CEACAM5 as a stemness-related inhibitory immune checkpoint in pancreatic cancer
    Shi, Haojun, Tsang, Yiusing, Yang, Yisi · 2023 · Figshare
  63. Additional file 2 of Identification of CEACAM5 as a stemness-related inhibitory immune checkpoint in pancreatic cancer
    Hao Shi, Tsang, Yiusing, Yang, Yisi · 2023 · Figshare
  64. Lung Cancer Cells Secrete Glutamine to Accumulate Tumor‐Associated Macrophages
    Joshua P. Reddy, Rebecca A. Clague, Beatriz P. Peixoto, Sara J. Bernstein, Emma E. Lauth, Clara Y. Takanohashi, Sophie C. Kim, Hiromi Inoue Wettersten · 2026 · Molecular Carcinogenesis
  65. Expression of αV and β3 integrins in primary breast tumors during cancer progression
    Marina V. Zavyalova, G. A. Kuznetsov, E.S. Grigoryeva, Л. А. Таширева, Завьялов Александр Васильевич, V. E. Popova, Алифанов Владимир Валерьевич, Пудова Елена Сергеевна, Перельмутер Владимир Михайлович · 2026 · Siberian Journal of Oncology
  66. A causal inference framework for identifying essential genes to enhance drug synergy prediction
    Huaiwu Zhang, Xinliang Sun, Jianxin Wang, Min Li, Jing Tang · 2026 · Bioinformatics
  67. Unraveling the Impact of KRAS Accessory Proteins on Oncogenic Signaling Pathways
    Vanshika Garg, Raphael N. H. M. Hofmann, Moazzam Saleem, Amin Mirzaiebadizi, Ghazaleh sadat hashemi, Tooba Hameed, Bahareh Jooyeh, Silke Pudewell, Mehrnaz Mehrabipour, Niloufar Mosaddeghzadeh et al. · 2026 · Cells
  68. Caractérisation de l'axe intégrine α5β1/protéine p53 dans les gliobastomes humains : application à une thérapie ciblée anti-tumorale
    Guillaume Renner · 2016 · theses.fr (ABES)
  69. Essais cliniques randomisés en oncologie dans les maladies rares ou en présence de sous-types rares identifiés par biomarqueurs
    Mohamed Amine Bayar · 2019
  70. Rôle de la tyrosine kinase SYK dans la régulation du processus métastatique du mélanome
    Émilien García · 2016 · theses.fr (ABES)
  71. La caractérisation de la mutation IDH1R¹³²H dans un modèle de gliome humain de haut grade par imagerie multimodale, une étude translationnelle in vitro et in vivo
    Alexandra Clément · 2020
  72. Role of Kindlin-1 in the Progression of Different Epithelial Cancers
    Paula Azorin · 2021
  73. Investigating the role of the centromeric histone variant CENP-A in cancer
    Charlène Renaud-Pageot · 2024 · theses.fr (ABES)
  74. Synergistic Regulation of Tumor Immunity by Integrins and Lectins: From Molecular Mechanisms to Dual-Targeted Therapy
    Rongyang Liu, Chen Liu, Xiaotong Guo, Peiyan Li, Yewei Niu, Jiawei Zhao, Jingyi Zhang, Xiaolin Su, Jian Chen, Jiamin Jin et al. · 2026 · International Journal of Molecular Sciences